City of Hope is recognized internationally for its ground-breaking discoveries and clinical trials for novel new agents to treat
a type of cancer that begins in plasma cells. We collaborate with other research institutions to create tomorrow’s treatments for patients at City of Hope today. We are the only Southern California member of the Multiple Myeloma Research Consortium, a collaboration of research organizations focused on rapidly bringing the most promising multiple myeloma treatments to patients.
Because of our vast experience in treating patients with this type of cancer, our specialists lead the field in improving outcomes for patients. City of Hope’s approach incorporates our nationally recognized stem cell transplantation program with many clinical protocols utilizing the newest agents for the treatment of myeloma.
Designated a Comprehensive Cancer Center by the National Cancer Institute, City of Hope is acknowledged as a leader in cancer research and in transplant trials and is heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib).
We offer the broadest range of therapeutic options available, including protocols developed here at City of Hope and funded in part by the National Institutes of Health. Through ongoing
our physicians and researchers continue to lead the way in improving outcomes in myeloma patients.
Just as every patient is different, we recognize that every multiple myeloma case is different. What distinguishes City of Hope in the treatment of patients with blood disorders is seamless continuity of care. From a
to treatment with the newest drugs in our clinical trials, to transplantation, patients are treated by the same team of doctors who see them through every phase of treatment and recovery. City of Hope also offers the expertise of geriatric oncologists who specialize in the treatment of older patients.
City of Hope is a national leader in transplant trials and heavily involved in new drug trials, including a recently approved novel agent for myeloma (Carfilzomib). City of Hope runs one of the largest and most successful
hematopoietic cell transplantation
(HCT) centers in the world. Since 1976, City of Hope has performed more than 11,000 transplants with excellent outcomes for patients from virtually every state and around the world.
Treatments vary depending on the specific type of myeloma and other factors such as the patient’s age, overall health and prior therapy. They include chemotherapy, stem cell transplantation and radiation therapy.
For more information on the myeloma program and treatments,